235 related articles for article (PubMed ID: 17932394)
1. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.
Ryan G; Martinelli G; Kuper-Hommel M; Tsang R; Pruneri G; Yuen K; Roos D; Lennard A; Devizzi L; Crabb S; Hossfeld D; Pratt G; Dell'Olio M; Choo SP; Bociek RG; Radford J; Lade S; Gianni AM; Zucca E; Cavalli F; Seymour JF;
Ann Oncol; 2008 Feb; 19(2):233-41. PubMed ID: 17932394
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study.
Yhim HY; Kang HJ; Choi YH; Kim SJ; Kim WS; Chae YS; Kim JS; Choi CW; Oh SY; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Lee JJ; Sung HJ; Kim HJ; Lee DH; Suh C; Kwak JY
BMC Cancer; 2010 Jun; 10():321. PubMed ID: 20569446
[TBL] [Abstract][Full Text] [Related]
3. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy.
Yhim HY; Kim JS; Kang HJ; Kim SJ; Kim WS; Choi CW; Eom HS; Kim JA; Lee JH; Won JH; Shim H; Huh J; Lee DH; Suh C; Kwak JY
Int J Cancer; 2012 Jul; 131(1):235-43. PubMed ID: 21823120
[TBL] [Abstract][Full Text] [Related]
4. [Prognosis analysis of primary breast diffuse large B cell lymphoma].
Zhu YH; Meng WJ; He LH; Jia YS; Tong ZS
Zhonghua Zhong Liu Za Zhi; 2019 Mar; 41(3):235-240. PubMed ID: 30917462
[No Abstract] [Full Text] [Related]
5. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
7. Clinicopathological Features, Treatment, and Prognosis in Primary Diffuse Large B Cell Lymphoma of the Breast: A Retrospective Study of 46 Patients.
Luo H; Yi P; Wang W; Li K; Meng L; Li J; Zeng W; Tang M
Med Sci Monit; 2019 Nov; 25():8671-8682. PubMed ID: 31734687
[TBL] [Abstract][Full Text] [Related]
8. Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers.
Ryan GF; Roos DR; Seymour JF
Clin Lymphoma Myeloma; 2006 Jan; 6(4):337-41. PubMed ID: 16507213
[TBL] [Abstract][Full Text] [Related]
9. Diffuse large B-cell lymphoma of the breast: a distinct entity?
Bierman PJ; Villanueva ML; Armitage JO
Ann Oncol; 2008 Feb; 19(2):201-2. PubMed ID: 18187483
[No Abstract] [Full Text] [Related]
10. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
[TBL] [Abstract][Full Text] [Related]
11. Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure.
Ludmir EB; Milgrom SA; Pinnix CC; Gunther JR; Westin J; Oki Y; Fayad LE; Medeiros LJ; Dabaja BS; Nastoupil LJ
Leuk Lymphoma; 2018 Dec; 59(12):2896-2903. PubMed ID: 29697005
[TBL] [Abstract][Full Text] [Related]
12. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
Yang BY; Yong WB; Zhu J; Zheng W; Zhang YT; Wang XP; Meng SN
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
[TBL] [Abstract][Full Text] [Related]
14. Primary malignant non-Hodgkin's lymphoma of the breast: a study of seven cases and literature review.
Mouna B; Saber B; Tijani el H; Hind M; Amina T; Hassan E
World J Surg Oncol; 2012 Jul; 10():151. PubMed ID: 22800119
[TBL] [Abstract][Full Text] [Related]
15. Primary breast non-Hodgkin's lymphoma: a large single center study of initial characteristics, natural history, and prognostic factors.
Validire P; Capovilla M; Asselain B; Kirova Y; Goudefroye R; Plancher C; Fourquet A; Zanni M; Gaulard P; Vincent-Salomon A; Decaudin D
Am J Hematol; 2009 Mar; 84(3):133-9. PubMed ID: 19199367
[TBL] [Abstract][Full Text] [Related]
16. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
Weng H; Shrestha PR; Hong H; Chen Z; Yu L; Yao Y; Zhang Z; Zou L; Zhu B; Zhou H; Liu X; Liu Y; Guo H; Huang H; Lin T
Cancer Med; 2023 Dec; 12(23):21188-21198. PubMed ID: 37997571
[TBL] [Abstract][Full Text] [Related]
17. Localized primary non-Hodgkin lymphoma of the breast.
Ha CS; Dubey P; Goyal LK; Hess M; Cabanillas F; Cox JD
Am J Clin Oncol; 1998 Aug; 21(4):376-80. PubMed ID: 9708637
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
19. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.
Ollila TA; Olszewski AJ
Curr Treat Options Oncol; 2018 Jun; 19(8):38. PubMed ID: 29931605
[TBL] [Abstract][Full Text] [Related]
20. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
